Division of Infectious Diseases and Immunology Research
At NYU Langone’s Division of Infectious Diseases and Immunology, we believe that research is the engine that drives new medical advances to protect and restore public health locally and globally. Research is an important part of our mission, and our goal is to translate scientific research into innovative ways to prevent, diagnose, and treat infectious diseases.
Our research activities cover the entire span of biomedical discovery—from preclinical laboratory research using animal models, to clinical studies and clinical trials that translate into clinical practice. We also conduct research on healthcare policy, education, and behavior.
We are dedicated to training the next generation of research leaders in the field of infectious diseases and immunology. Important research initiatives within our division include the Vaccine Center, NYU Langone Molecular Outbreak Program, Special Pathogens Program at NYC Health + Hospitals/Bellevue, and hepatitis C elimination studies, as well as research on Staphylococcus aureus bacteria, hepatitis B, influenza, universal flu vaccine, flaviviruses, and yellow fever virus vaccines.
Core Faculty Investigators
Benjamin J. Eckhardt, MD
Assistant Professor, Department of Medicine
Lead Investigator, Hepatitis C Elimination Studies
Ramin Herati, MD
Assistant Professor, Department of Medicine
Mark J. Mulligan, MD
Director, Division of Infectious Diseases and Immunology
Director, Vaccine Center
The Thomas S. Murphy Sr. Professor, Department of Medicine
Bo Shopsin, MD, PhD
Associate Director, Research, Division of Infectious Diseases
Director, Molecular Epidemiology Director, Antimicrobial-Resistant Pathogens
Program Associate Director of MSTP Curriculum and Programming
Associate Professor, Department of Microbiology
Scott A. Weisenberg, MD
Medical Director, NYU Langone Infectious Disease Associates
Medical Director, Travel Medicine Program
Clinical Associate Professor, Department of Medicine
Faculty Publications
Our faculty publish their research in leading peer-reviewed journals. Learn more about their recent publications.
SARS-CoV-2 infection predisposes patients to coinfection with Staphylococcus aureus
MBio. 2024 Aug 14; 15:e0166724
Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities
Journal of racial & ethnic health disparities. 2024 Aug ; 11:2109-2119
A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13
ACS chemical biology. 2024 Jul 19; 19:1593-1603
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination
Annals of clinical & translational neurology. 2024 Jul ; 11:1750-1764
SARS-CoV-2 inflammation durably imprints memory CD4 T cells
Science immunology. 2024 Jun 21; 9:eadj8526
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults
Clinical infectious diseases. 2024 Jun 14; 78:1757-1768
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex
Vaccine. 2024 May 22; 42:3365-3373
The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination
Clinical infectious diseases. 2024 May 15; 78:1235-1239